Goldman Sachs Group Inc. Has $497,000 Holdings in Precigen, Inc. $PGEN

Key Points

• Goldman Sachs Group Inc. reduced its holdings in Precigen, Inc. by 34.3%, now owning approximately 333,512 shares valued at $497,000.
• Insider transactions include Director Nancy H. Agee purchasing 15,360 shares, while Director Randal J. Kirk sold over 3.5 million shares, reflecting notable trading activity among corporate insiders.
• Precigen has recently received upgraded ratings from multiple analysts, with a consensus price target of $8.25 indicating positive market sentiment towards the stock.

Goldman Sachs Group Inc. lessened its position in shares of Precigen, Inc. (NASDAQ:PGEN - Free Report) by 34.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 333,512 shares of the biotechnology company's stock after selling 174,020 shares during the period. Goldman Sachs Group Inc. owned about 0.11% of Precigen worth $497,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in PGEN. BNP Paribas Financial Markets bought a new position in Precigen during the 4th quarter worth about $27,000. Apella Capital LLC bought a new position in Precigen during the 1st quarter worth about $40,000. Voya Investment Management LLC increased its holdings in Precigen by 142.9% during the 1st quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 21,633 shares in the last quarter. ProShare Advisors LLC increased its holdings in Precigen by 26.6% during the 4th quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock worth $58,000 after purchasing an additional 10,900 shares in the last quarter. Finally, Strs Ohio bought a new position in Precigen during the 1st quarter worth about $70,000. Institutional investors own 33.51% of the company's stock.

Insider Transactions at Precigen

In other Precigen news, Director Nancy H. Agee purchased 15,360 shares of Precigen stock in a transaction that occurred on Tuesday, August 19th. The stock was acquired at an average price of $3.20 per share, for a total transaction of $49,152.00. Following the completion of the acquisition, the director owned 192,196 shares of the company's stock, valued at approximately $615,027.20. This trade represents a 8.69% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Randal J. Kirk sold 3,596,892 shares of Precigen stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $3.68, for a total value of $13,236,562.56. Following the transaction, the director owned 8,520,537 shares of the company's stock, valued at $31,355,576.16. The trade was a 29.68% decrease in their position. The disclosure for this sale can be found here. Insiders have purchased 41,005 shares of company stock valued at $167,651 in the last quarter. 47.10% of the stock is currently owned by corporate insiders.

Precigen Stock Performance

Precigen stock opened at $3.48 on Friday. Precigen, Inc. has a 52 week low of $0.65 and a 52 week high of $5.22. The stock has a market capitalization of $1.04 billion, a P/E ratio of -8.29 and a beta of 1.82. The stock has a 50-day simple moving average of $3.07 and a 200 day simple moving average of $2.05.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%.The business had revenue of $0.86 million during the quarter, compared to analysts' expectations of $0.67 million. Research analysts forecast that Precigen, Inc. will post -0.32 earnings per share for the current year.

Analysts Set New Price Targets

PGEN has been the subject of a number of research reports. Citigroup reiterated an "outperform" rating on shares of Precigen in a report on Tuesday, August 19th. Wall Street Zen upgraded Precigen from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. JPMorgan Chase & Co. raised Precigen from an "underweight" rating to a "neutral" rating in a research report on Friday, August 15th. HC Wainwright restated a "buy" rating and issued a $8.50 price target on shares of Precigen in a research note on Tuesday, August 19th. Finally, JMP Securities upped their price objective on Precigen from $6.00 to $8.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 19th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $8.25.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.